The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities.  | In a Worker Adjustment and Retraining Notification Act alert filed this ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ...

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can ...

Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer ...

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

>40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is developing ...

Even with all that, Keytruda's empire, although weakened, should remain strong until the next decade. Merck has received ...

A Phase III switch study occurring over 96 weeks has demonstrated that US pharma giant Merck & Co’s doravirine/islatravir (DOR/ISL) sustains durable viral suppression with stable safety outcomes in ...

RAHWAY, NJ — The Research & Development Council of New Jersey celebrated the state’s top inventors, scientists, and research organizations at the 46th annual Edison Patent Awards Ceremony and ...

Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...